GLUE Latest Press Releases

-- October 2, 2026 --

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- October 1, 2026 --

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk Globe Newswire 7:00 AM

-- September 30, 2026 --

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk Globe Newswire 4:01 PM

-- September 8, 2026 --

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Globe Newswire 7:00 AM

-- September 2, 2026 --

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 1, 2026 --

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- August 24, 2026 --

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer Globe Newswire 7:00 AM

-- August 6, 2026 --

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Globe Newswire 7:00 AM

-- July 2, 2026 --

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- June 2, 2026 --

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes